Call for sponsors & exhibitors
Venoms 2019 invites commercial sponsorship for demonstration of R&D and laboratory supplies related to field and laboratory venom research. We offer a number of highly competitive packages (examples below). If your needs are not covered by the offered packages please contact us in the first instance and we shall do our best to develop a package to suit your requirements.
- Gold: Includes a speaker slot AND an exhibition stand, plus four free passes (max 3)
- Silver: Includes a speaker slot OR an exhibition stand, plus three free passes (max 3)
- Bronze: Includes exhibition stand, plus two free passes (Max 3)
- Drinks Reception
- Delegate Bags (max 2)
- Delegate Badges (max 2)
- Event Documentation (max 2)
- Exhibition stand
For Booking Form, terms and conditions, and further information about packages and other promotional opportunities email at:
Silanes was born on November 4, 1943 as a medical prescription laboratory. Today is a solid company that has evolved according to the requirements of quality and innovation maintaining a tradition of trust and commitment to its various stakeholders, such as doctors and members of the health sector, employees, customers, partners, researchers, suppliers, authorities, etc., with the motivation of the world every day to provide better solutions to health.
We are an innovative company that set aside 10% of our sales to research and development, patents and generators being agreements academia-industry collaboration. Aware of the challenges imposed on us by an increasingly globalized world, we seek to expand our coverage to other countries by forming strategic alliances with companies in the industry with the launch of a subsidiary in Spain that allows us to generate innovative projects in other continents.
The Instituto Bioclon is a subusidiary company of Silanes and came about as a result of this union 1990. It emerged to take advantage of the opportunities for developing new biotechnologies and for becoming a world leader in the research, development, and production.
Bioclon-Silanes is the creator of third generation antivenoms of worldwide level, whose biotechnological characteristics make them different, that are highly safe, broadly efficacious, and having had no reports of severe secondary effects. They are produced using a technology that is 100% that of Bioclon-Silanes, and protected by patents in several countries. Our antivenoms are currently marketed in Mexico, Central and South America, United States of America, Europe, Africa, and the Middle East through a regionalization program
Bioclon-Silanes is the only Mexican company that has obtained the designation “orphan drug” (the non-existence of a drug or medication for treating a specific disease) by the Food and Drug Administration (FDA) of the United States of America.
VINS Bioproducts Limited entered the arena of biologicals and bio-pharmaceuticals at the turn of the century with a view to produce life saving drugs for rural areas. Early on, the company focused on finding remedies for diseases that are endemic in India, the tropics and other less developed nations. True to its initial objective, the company commenced work to develop AntiSnake Venom Serum (ASVS), which was launched in early 2000. VINS’ ASVS, is a life saving product much needed in rural areas where people engaged in agriculture activities are regularly exposed to snake bites.
The product was well accepted and enjoys today, a market share of almost 40% of the Indian ASVS market. Spurred on by the initial success, the company took up the development of ASVS (Polyvalent from different African snake species including for deadly Black Mamba species). Today Vins manufactures several Snake Venom Antiserum country specific to the requirement by the MOH of various countries.
Anti Rabies Serum (ARS). World Health Organization (W.H.O.) estimates that 75% of deaths caused by rabies world-wide, occur in India, Bangladesh and Pakistan alone. W.H.O. recommends Anti Rabies Serum (ARS) along with anti rabies vaccine (ARV) to be injected in all Category III and immuno- compromised Category II rabies cases. The other products are Tetanus Antitoxin, and Diphtheria Antitoxin.
MicroPharm Limited is a developer and manufacturer of therapeutic polyclonal antibodies for human and veterinary use. The Company’s core expertise lies in the raising of ovine antisera containing high levels of specific antibodies directed against antigens such as toxic molecules or viruses and the subsequent purification and modification of such antibodies to produce a range of immunotherapeutic products for clinical use. All are designed to treat acute, life-threatening emergencies, have been developed at the request of the medical profession and are required urgently either because no alternative exists or because any alternative is ineffective and/or unsafe. MicroPharm currently produces two antivenoms, ViperaTAb® for the treatment of envenomation by the European adder and EchiTAbG™ for the treatment of the carpet viper, Echis ocellatus. The Company has a number of products in development including: PolyCAb for the treatment of severe C. diff.; ColchiBIND for the treatment of colchicine poisoning; EBOTAb for the treatment of Ebola Virus Disease and ViperaVet™, for the treatment of dogs envenomed by one of the four medically important species of Vipera (adder) found throughout Western Europe. MicroPharm’s collaborators include Public Health England, University of Oxford, University of Leeds and the University of Edinburgh.
The Global Snakebite Initiative (http://www.snakebiteinitiative.org) is an internationally-active, non-profit, charitable organisation, registered in Australia, but with world-wide vision, aims and membership. It is led by snake-bite experts who are dedicated to improving access to good quality, robustly tested, safe, effective antivenoms in the world’s poorest communities. It strives to provide a collaborative framework to address the neglected global tragedy of snake-bite envenoming. The Global Snakebite Initiative has been endorsed by the membership of the International Society on Toxinology (IST). Several senior representatives of GSI will be attending the meeting, including Professor José María Gutiérrez, Professor David Warrell, Professor Juan Calvete, Professor Alan Harvey, Professor Robert Harrison, Dr David Williams and Dr Aniruddha Ghose.
OxonLab provides 1-, 2- and 5-day basic biomedical/biosciences laboratory training courses at Oxford. One-day courses include: i) Essential laboratory skills; ii) Essential molecular biology iii) Essential molecular biology & bioinformatics; and iv) Molecular separation methods. Two-day courses include: i) Discovering molecular biology; ii) Discovering molecular biology & bioinformatics; and iii) Discovering microbiology. Five-day courses, providing in-depth training, include: i) Extended molecular biology laboratory skills; and ii) Extended microbiology laboratory skills. The training is provided by experienced laboratory scientists from the University of Oxford, Oxford hospitals and Oxford Brookes University.
In addition, OxonLab also offers one-day workshop in Intellectual property and commercialisation in biosciences, Health & Safety, and Bioethics. These taught workshops provide essential background in important areas, such as intellectual property in biosciences, patent applications, patent searches and regulations, good laboratory practices, biosafety & bioethics, working with GMOs, and COSHH regulations.
For further information, drop us an email at Training@LPMHealthcare.com and visit our website http://laboratorycourses.com.
Twitter: https://twitter.com/oxonlab | #OxonLab
Venoms 2019 Sponsors
We are happy to waive the basic open access fee of Venoms & Toxins 2019 delegates for manuscript submitted until 30 September 2019, as long as the manuscripts are prepared according to the published guidelines.
The Journal (ISSN: 2044-0324) will publish high-quality peer-reviewed articles addressing most aspects of therapeutic, molecular, biochemical and evolutionary research on venoms, and envenomation. The Journal aims at providing an efficient route to fast-track publication, within 10-12 weeks of manuscript submission if accepted. Furthermore, manuscripts will be made available online in their final form generally within 2-3 weeks of final acceptance.
The Journal will be primarily published online but on sufficient demand for printed version journal hard copies may also be provided to individuals and institutions.
Manuscripts in the following categories will be considered for publication: reviews, mini-reviews, research articles, research reports, research letters, clinical reports, case studies, new methods and technologies, meeting reports and commercial, patent and product news and editorials.
The Journal is currently indexed in:
- PubMed Central
- PMC Canada
- The Directory of Open Access Journals
- Google Scholar
- OPEN J-Gate
- Chemical Abstracts Service (CAS)
- Academic Search Complete (EBSCO)